RNA-sequencing of serial biopsies from 3 patients treated with Capivasertib (AZD5363)

ABSTRACT: First line treatment with AKT inhibitors combined with paclitaxel improves outcomes of metastatic TNBC, especially in tumors that harbor mutations in PTEN/PIK3CA/AKT1. In this work, we refine the composite response biomarker to AZD5363 in this setting, which is relevant to inform the clinical development of these drugs.

ORGANISM(S): Homo sapiens

PROVIDER: GSE144794 | GEO | 2020/06/30

REPOSITORIES: GEO